Vipul Jain, MD
Pulmonary Disease · Fresno, CANPI 1295927911
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,800 of the $7,418 with a category attached, or 91.7%. AstraZeneca accounts for 67.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $6,047 and has fallen 90.9% since, to $552 in 2023.
Across 17 payments — averaging $436.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Viiv Healthcare Company$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$500
- GSK$237
- Grifols USA, LLC$63
- Genentech USA, Inc.$11
Across 4 payments — averaging $10,718 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$28K
- Medtronic$15K
What the payments were for
- Speaking & faculty fees$6,80092%
- Travel & lodging$1162%
- Food & beverage$5027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $5,007 |
| Viiv Healthcare Company | 1 | $1,600 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $500 |
| GSK | 6 | $237 |
| Grifols USA, LLC | 1 | $63 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,418 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 38 | $135,878 |
| Dupixent SyringeDupilumab | 21 | $73,548 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $49,697 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $38,548 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,193 |
| Arnuity ElliptaFluticasone Furoate | 16 | $6,308 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,729 |
| BreynaBudesonide/Formoterol Fumarate | 28 | $2,651 |
| Roflumilast | 14 | $1,259 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,138 |
| Montelukast Sodium | 40 | $479 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $224 |
| Azithromycin | 13 | $111 |
| Prednisone | 16 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $237 | $230,431170 claims |
| AstraZenecaSymbicort | $5,007 | $4,72916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Fresno
- Vijay BalasubramanianFresno$529K
- Vijai DanielFresno$471K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.